Biopharma financings from January through October 2025 totaled $61.45 billion, roughly in line with the $61.04 billion raised ...

Antibody-drug conjugates (ADCs) carrying topoisomerase I (TOP1) inhibitors, such as trastuzumab deruxtecan (T-DXd), have ...

Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced ...

Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after ...

Phase II data being presented at the American Association for the Study of Liver Diseases annual meeting indicate drug ...

Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated ...

UNESCO has adopted the first set of global standards on the ethics of neurotechnology amid the rapid advancement in the ...

Zhongshan Innovation New Drug Development Co. Ltd. has described conjugates comprising a chelating ligand moiety, a fibroblast activation protein α (FAP) ligand and integrin αvβ3 or integrin αvβ6 ...

Chinese Academy of Medical Sciences has divulged imidazopyridine derivatives reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the ...

Shares of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) were trading at $1.65, down $2.45, or 59%, after the company disclosed phase II results from the Bestow trial testing tegoprubart, which targets ...

Chengdu Zeling Biomedical Technology Co. Ltd. has identified salts of deuterated compounds acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of ...